Boron
neutron capture therapy (BNCT) is a binary therapeutic approach.
Nonradioactive boron-10 atoms accumulated in tumor cells combining
with the neutron beams produce two highly energetic particles that
could eradicate the cell that takes it and the neighboring cells.
Small molecules that carry boron atom, e.g. 5- and 6-boronated and
2,7-diboronated tryptophans, were assessed for their boron accumulation
in U87-MG, LN229, and 3T3 for BNCT. TriBoc tryptophan, TB-6-BT, shows
boron-10 at 300 ppm in both types of tumor cells with a tumor to normal
ratio (T/N) of 5.19–5.25 (4 h). TB-5-BT and DBA-5-BT show boron-10
at 300 ppm (2 h) in U87-MG cells. TB-5-BT exerts a T/N of >9.66
(1
h) in LN229 compared with the current clinical boronophenyl alanine
with a highest T/N of 2.3 (1 h) and accumulation concentration of
<50 ppm. TB-5-BT and TB-6-BT warrant further animal study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.